Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857662 | 0.99 | HRH3 (0.59) | HRH3MAPK1KDM4ECHKAL3MBTL1 | |
| SCHEMBL9202121 | 0.89 | CHKA (0.55) | HRH3MAPK1KDM4ECHKAL3MBTL1 | |
| SCHEMBL17075531 | 0.88 | HRH3 (0.61) | HRH3MAPK1KMT2ANPC1RAB9A | |
| SCHEMBL18173335 | 0.88 | MAPK1 (0.47) | HRH3MAPK1KDM4ECHKAL3MBTL1 | |
| SCHEMBL15198051 | 0.86 | HRH3 (0.58) | HRH3MAPK1KDM4ECHKAL3MBTL1 | |
| SCHEMBL31043166 | 0.85 | HRH3 (0.46) | HRH3MAPK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL29250316 | 0.85 | KDM5C (0.47) | HRH3MAPK1KDM4EL3MBTL1KMT2A | |
| SCHEMBL6949028 | 0.85 | KDM4E (0.46) | HRH3MAPK1KDM4EL3MBTL1KMT2A | |
| Hydrochloric Acid SCHEMBL30583829 | 0.85 | KDM5C (0.47) | HRH3MAPK1KDM4EL3MBTL1KMT2A | |
| SCHEMBL22465802 | 0.83 | KDM4E (0.44) | HRH3MAPK1KDM4EL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110938076-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-112898308-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3190113-B1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-05-19 | — | — | EP | disclosed |
| EP-3190113-B1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-05-19 | — | — | EP | disclosed |
| CN-110759916-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-110938076-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-10555949-B2 | Pyrrolopyrimidine compounds used as TLR7 agonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-11 | — | — | US | disclosed |
| US-10555949-B2 | Pyrrolopyrimidine compounds used as TLR7 agonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-11 | — | — | US | disclosed |
| CN-110759916-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-106661034-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2019-11-29 | — | — | CN | disclosed |
| US-9962388-B2 | Pyrrolopyrimidine compounds used as TLR7 agonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-05-08 | — | — | US | disclosed |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| EP-3190113-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
| EP-3190113-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
| CN-106661034-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| WO-2016023511-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | 正大天晴药业集团股份有限公司 | 2016-02-18 | — | — | WO | disclosed |
| US-5114945-A | Spiropiperidine derivatives | GLAXO GROUP LIMITED (GB) | 1992-05-19 | — | — | US | disclosed |
| EP-0330461-A2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555949-B2 | Pyrrolopyrimidine compounds used as TLR7 agonist | TLR7, TLR9, TLR1 | HRH3 744/4885MAPK1 251/4885KDM4E 1970/4885 |
| US-20170273983-A1 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST | TLR7, TLR9, TLR1 | HRH3 744/4885MAPK1 251/4885KDM4E 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.